A groundbreaking new drug developed by Bayer is undergoing review for approval in Korea. The drug is known to inhibit disease progression in chronic kidney disease (CKD) patients with diabetes.

According to industry sources on the 8th, Bayer applied for the approval of its ‘finerenone (Kerendia tab)’ to the Ministry of Food and Drug Safety in Korea. Finerenone, which was developed by Bayer, is considered to be a potential global blockbuster by the company.

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that selectively acts on mineralocorticoid receptors to block harmful effects on the kidneys and the heart. It is reported to be particularly us